Why Bryan Johnson's CJC-1295 with DAC Experiment Failed: Protocol Errors, Metabolic Side Effects, and What Peptide Users Should Learn

Bryan Johnson's self-experiment with CJC-1295 with DAC produced textbook adverse effects from a predictable mechanism — and the data offers a clearer lesson about peptide pharmacology than about peptide safety overall.

What Johnson Reported

In mid-2026, Bryan Johnson — the tech entrepreneur behind Project Blueprint — publicly shared the results of a self-administered peptide experiment involving CJC-1295 with DAC. After two doses over ten days, his biometric tracking showed the following changes from baseline:

Growth hormone (GH): increased approximately +800% (from <0.1 ng/mL to ~0.8 ng/mL)
Insulin resistance score: up +50%
Fasting glucose: up +20% (from 90 mg/dL to 108 mg/dL — crossing into the impaired fasting range)
C-peptide: up +52.9% (from 0.51 to 0.78 ng/mL), indicating meaningfully greater pancreatic insulin output
Morning cortisol: up +11.6% (from 12.1 to 13.5 mcg/dL)
REM sleep: down -23% (from roughly 1h 49m to 1h 24m per night)

These shifts manifested clinically as near-comatose fatigue and severely disrupted sleep within 48 hours of his first injection. Johnson's public conclusion was that peptides are dangerous and that self-experimenters are "flying blind."

That conclusion misidentifies the cause. The adverse outcomes were pharmacologically predictable from the specific formulation he used and the doses he administered — not from GHRH peptide therapy as a category.

The Mechanism: How GH Is Supposed to Work

Before examining what went wrong, it helps to understand the physiology CJC-1295 is intended to work with.

The pituitary gland does not release growth hormone in a continuous, flat stream. It releases GH in discrete, high-amplitude pulses — primarily during slow-wave (deep) sleep, typically 4–6 pulses over 24 hours. Between pulses, GH levels fall back toward a near-zero baseline. This baseline drop is physiologically important: it allows GH receptors to clear and reset their sensitivity, and it keeps downstream effects — including effects on insulin signalling — transient rather than sustained.

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to secrete GH. The key question for any CJC-1295 formulation is how long that signal lasts.

Error #1 — The DAC Formulation Overrides Pulsatility

The "DAC" in CJC-1295 with DAC stands for Drug Affinity Complex. It is a chemical modification that allows the peptide to bind reversibly to albumin in the bloodstream, dramatically extending its half-life. CJC-1295 without DAC has a half-life of roughly 30 minutes. CJC-1295 with DAC has a half-life of approximately 6–8 days.

The practical consequence: a single injection of the DAC formulation creates a sustained, near-continuous elevation of GH signalling lasting the better part of a week. This is structurally opposite to the body's pulsatile GH rhythm.

Johnson's team reportedly chose the DAC formulation because they believed it had the most controlled trial data. That reasoning misses the pharmacokinetic point entirely. Having more trial data does not make a continuous-release formulation appropriate where pulsatile physiology is the target.

What sustained GH elevation does to metabolism:

Insulin resistance: GH is physiologically anti-insulin — it mobilises fat and reduces cellular glucose uptake. In natural pulsatile cycles, the body handles this briefly and then restores sensitivity during the inter-pulse baseline. Sustained multi-day GH elevation removes that recovery window, leading to receptor downregulation and persistent glucose intolerance. Johnson's fasting glucose crossing 108 mg/dL and his pancreas secreting over 50% more insulin (C-peptide) to compensate are textbook consequences.

Sleep architecture disruption: GH release and slow-wave sleep are tightly coupled in a bidirectional feedback loop. Continuous synthetic GH elevation signals the brain that no further nocturnal pulse is needed, disrupting the normal cycle. This is consistent with Johnson's -23% REM loss and elevated morning cortisol, which reflects HPA axis perturbation.

Chronic IGF-1 elevation: Both sources note that sustained GH signalling keeps IGF-1 chronically elevated. One source flags the association with increased cancer risk at high levels over time, though this is a theoretical long-term concern rather than something demonstrated directly in Johnson's ten-day experiment.

These effects were not idiosyncratic reactions. They were predictable from the mechanism before the first injection was administered.

Error #2 — Aggressive and Rapidly Escalating Doses

The formulation problem was compounded by the dosing schedule. In clinical peptide practice, growth hormone secretagogues are introduced at low doses to allow receptor pathways and insulin feedback loops to adapt. Johnson's reported doses were:

	Johnson's Protocol	Clinical Starting Range (No DAC)
Dose 1	1,200 mcg (1.2 mg)	100–300 mcg
Dose 2	1,800 mcg (1.8 mg)	Titrated slowly over weeks

Johnson began at four to twelve times the typical clinical starting dose and escalated within days. Hormones act via receptor saturation; once receptors are fully occupied, additional hormone does not produce proportionally greater benefit. Instead, excess hormone circulates unbound, spilling into off-target pathways — contributing to the fluid retention, cortisol elevation, and acute fatigue he reported.

It is worth being transparent about evidence quality here: the clinical dose ranges cited above come from the source articles themselves, which reflect clinical practice guidelines rather than a specific named randomised trial. Users should note this distinction.

The Clinical Alternative: CJC-1295 (No DAC) + Ipamorelin

In clinical peptide practice, the DAC formulation is rarely the first choice for longevity or recovery applications. The more widely used approach pairs:

CJC-1295 without DAC — with its ~30-minute half-life, it acts as a brief GHRH signal, stimulating a controlled GH pulse from the pituitary and then clearing rapidly. This preserves the inter-pulse baseline, maintaining insulin sensitivity and avoiding prolonged receptor exposure.

Ipamorelin — a selective growth hormone secretagogue that mimics ghrelin to amplify GH pulse magnitude. Importantly, ipamorelin is selective: at standard doses it does not substantially stimulate cortisol or prolactin, making it a cleaner signal than older non-selective secretagogues.

Together — typically micro-dosed at around 100–150 mcg of each, administered before sleep when natural GH pulses are largest — the two compounds work synergistically. CJC-1295 (no DAC) drives GH release; ipamorelin suppresses somatostatin (the pituitary's natural "stop signal"), amplifying the pulse. The result is a pulsatile GH elevation that mirrors natural physiology, clears within hours, and leaves sleep architecture and insulin sensitivity intact.

The outcomes profile of this pairing is fundamentally different from CJC-1295 with DAC precisely because the pharmacokinetics are different — same compound name, entirely different physiological consequence.

One important caveat: both sources reflect clinical practice perspectives from a health-optimisation company. Readers should understand that robust, long-term randomised controlled trial data on CJC-1295 (no DAC) + ipamorelin combinations in healthy adults is limited in the published literature. The mechanistic reasoning is sound, but it should not be treated as equivalent to a large trial demonstrating safety and efficacy.

What a MyKine User Should Track

If you are using or considering a GHRH peptide protocol, Johnson's experiment illustrates precisely which biomarkers are most likely to move — and in which direction if the protocol is off:

Fasting glucose and HOMA-IR (or equivalent insulin resistance scoring): The most sensitive early signal for GH-driven metabolic disruption. Track before starting and within the first two weeks.
C-peptide or fasting insulin: A rising C-peptide alongside rising glucose confirms the pancreas is working harder to compensate — an early warning before full insulin resistance develops.
Morning cortisol: Elevated AM cortisol alongside fatigue suggests HPA axis perturbation, not just poor sleep.
Sleep staging (deep sleep and REM): Wearable sleep tracking can detect architectural shifts within days. A drop in deep sleep or REM concurrent with a new peptide is a meaningful signal.
IGF-1: Relevant on longer protocols; reflects cumulative GH signalling load.

None of these require advanced testing — most are available through standard labs and consumer wearables. The point is to establish a genuine baseline before any protocol begins, not after problems emerge.

Practical Takeaway

The formulation determines the physiology. CJC-1295 with DAC (6–8 day half-life) produces continuous GH elevation; CJC-1295 without DAC (~30 min half-life) produces a brief pulse. Same compound name, opposite pharmacological behaviour.
Johnson's adverse effects were mechanism-predictable. Insulin resistance, sleep disruption, and cortisol elevation are direct, documented consequences of sustained GH elevation — not evidence that GHRH peptides are inherently dangerous.
Starting dose matters. Beginning at 1,200–1,800 mcg with the DAC formulation is far outside standard clinical practice. Dose and titration speed are not minor details.
Pulsatile mimicry is the clinical target. The CJC-1295 (no DAC) + ipamorelin combination is designed to work with the body's GH rhythm, not override it — though long-term RCT data in healthy adults remains limited.
Track before you start. Fasting glucose, insulin or C-peptide, morning cortisol, IGF-1, and sleep staging should all have baselines established before any GH secretagogue protocol begins.
Mechanism literacy matters more than compound name. The lesson from Johnson's experiment is not "avoid peptides" — it is that two products sharing a name can have completely different physiological effects based on a single molecular modification.